[{"address1": "301 Binney Street", "address2": "3rd Floor", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "857 259 3860", "website": "https://scholarrock.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 150, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jay Thomas Backstrom M.D., M.P.H.", "age": 68, "title": "President, CEO & Director", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 1071673, "exercisedValue": 0, "unexercisedValue": 3439375}, {"maxAge": 1, "name": "Mr. Edward H. Myles MBA", "age": 51, "title": "CFO, COO & Treasurer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 720786, "exercisedValue": 0, "unexercisedValue": 857292}, {"maxAge": 1, "name": "Ms. Tracey M. Sacco M.B.A.", "age": 47, "title": "Chief Commercial Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 548855, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mo  Qatanani Ph.D.", "age": 50, "title": "Chief Scientific Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Rushmie  Nofsinger", "title": "Vice President of Corporate Affairs & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Junlin  Ho J.D.", "age": 44, "title": "General Counsel & Corporate Secretary", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 563729, "exercisedValue": 0, "unexercisedValue": 112564}, {"maxAge": 1, "name": "Ms. Caryn  Parlavecchio", "age": 51, "title": "Chief Human Resources Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lisa Amaya Price", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin  Moore", "age": 48, "title": "Senior Vice President of Finance", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Iarrobino", "title": "Senior Vice President of Clinical Development & Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 9, "overallRisk": 7, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 7.42, "open": 26.275, "dayLow": 25.15, "dayHigh": 34.38, "regularMarketPreviousClose": 7.42, "regularMarketOpen": 26.275, "regularMarketDayLow": 25.15, "regularMarketDayHigh": 34.38, "beta": 0.824, "forwardPE": -17.761658, "volume": 42170180, "regularMarketVolume": 42170180, "averageVolume": 754150, "averageVolume10days": 1165870, "averageDailyVolume10Day": 1165870, "bid": 24.68, "ask": 34.36, "bidSize": 200, "askSize": 800, "marketCap": 2743517440, "fiftyTwoWeekLow": 6.48, "fiftyTwoWeekHigh": 34.38, "fiftyDayAverage": 8.7266, "twoHundredDayAverage": 12.3641, "currency": "USD", "enterpriseValue": 2621068288, "floatShares": 55453804, "sharesOutstanding": 80032600, "sharesShort": 16620796, "sharesShortPriorMonth": 14913742, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.2077, "heldPercentInsiders": 0.0121, "heldPercentInstitutions": 1.14028, "shortRatio": 28.15, "shortPercentOfFloat": 0.44919997, "impliedSharesOutstanding": 80032600, "bookValue": 1.67, "priceToBook": 20.526945, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -203846000, "trailingEps": -2.22, "forwardEps": -1.93, "enterpriseToEbitda": -12.653, "52WeekChange": 0.041403532, "SandP52WeekChange": 0.3069358, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "SRRK", "underlyingSymbol": "SRRK", "shortName": "Scholar Rock Holding Corporatio", "longName": "Scholar Rock Holding Corporation", "firstTradeDateEpochUtc": 1527255000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d4172360-ba22-3374-b294-8dd0e33412b6", "messageBoardId": "finmb_548810128", "gmtOffSetMilliseconds": -14400000, "currentPrice": 34.28, "targetHighPrice": 37.0, "targetLowPrice": 18.0, "targetMeanPrice": 30.57, "targetMedianPrice": 30.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 190494000, "totalCashPerShare": 2.38, "ebitda": -207144992, "totalDebt": 68044000, "quickRatio": 5.814, "currentRatio": 6.037, "debtToEquity": 50.924, "returnOnAssets": -0.51201, "returnOnEquity": -1.21293, "freeCashflow": -90118624, "operatingCashflow": -168603008, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-08"}]